Prenatally Diagnosed Cardiac Tumors and Tuberous Sclerosis Complex: A Single-Center Experience

Overview

Journal Children (Basel)

Date 2025 Jan 25

PMID 39857925

Authors

Matija Bakos

Dora Jelinek

Ana Coric Ljoka

Nada Sindicic Dessardo

Dalibor Saric

Ruza Grizelj

Affiliations

Soon will be listed here.

Abstract

Background/objectives: Cardiac rhabdomyoma (CR), the most frequently occurring fetal cardiac tumor, is often an early marker of tuberous sclerosis complex (TSC). This study evaluates outcomes of fetuses with prenatally diagnosed cardiac tumors managed at a single tertiary center.

Methods: Medical records of fetuses diagnosed with cardiac tumors between 2009 and 2024 were retrospectively reviewed.

Results: Sixteen cases were identified, with a median follow-up of 6.7 years. TSC was confirmed in 14 cases (88%). Multiple tumors were observed in 13 cases (81%), while 3 cases (19%) had solitary tumors. Both non-TSC cases involved solitary tumors. Cardiac complications (arrhythmias, conduction disorders, and hemodynamic abnormalities) occurred in 38% of cases prenatally and 69% postnatally, with larger tumor diameters significantly associated with complications ( = 0.02). No fetal hydrops or mortality occurred; however, one child died at age five due to a seizure. Postnatal tumor regression occurred in 56% of cases and complete regression in 38% by a median age of 2.3 years (range: 0.6-4.4). One tumor remained stable. Brain MRI revealed TSC-related changes in all TSC-affected patients except one, who had a developmental brain anomaly. Most TSC patients experienced epilepsy (71%) and developmental delays.

Conclusion: While CRs are typically benign and regress spontaneously, their strong association with TSC highlights the importance of early diagnosis and family counseling. TSC-related epilepsy and psychomotor delays significantly impair the quality of life. Early mTOR inhibitor therapy offers promise in mitigating TSC-related complications and improving outcomes.

References

Park H, Chang C, Choi S, Oh S, Roh C . Sirolimus therapy for fetal cardiac rhabdomyoma in a pregnant woman with tuberous sclerosis. Obstet Gynecol Sci. 2019; 62(4):280-284. PMC: 6629989. DOI: 10.5468/ogs.2019.62.4.280. View

Peng L, Cai Y, Wu J, Ling W, Wu Q, Guo S . Prenatal diagnosis and clinical management of cardiac rhabdomyoma: a single-center study. Front Cardiovasc Med. 2024; 11:1340271. PMC: 10904520. DOI: 10.3389/fcvm.2024.1340271. View

Holley D, Martin G, Brenner J, Fyfe D, Huhta J, Kleinman C . Diagnosis and management of fetal cardiac tumors: a multicenter experience and review of published reports. J Am Coll Cardiol. 1995; 26(2):516-20. DOI: 10.1016/0735-1097(95)80031-b. View

Yuan S . Fetal Primary Cardiac Tumors During Perinatal Period. Pediatr Neonatol. 2017; 58(3):205-210. DOI: 10.1016/j.pedneo.2016.07.004. View

Wang X, Ding Y, Zhou Y, Yu L, Zhou S, Wang Y . Prenatal diagnosis and intervention improve developmental outcomes and epilepsy prognosis in children with tuberous sclerosis complex. Dev Med Child Neurol. 2022; 64(10):1230-1236. DOI: 10.1111/dmcn.15265. View

Braun M, Riney K . Have epilepsy outcomes changed for children with tuberous sclerosis complex in Queensland, Australia?. Epilepsia. 2024; 65(9):2709-2717. DOI: 10.1111/epi.18069. View

Harding C, Pagon R . Incidence of tuberous sclerosis in patients with cardiac rhabdomyoma. Am J Med Genet. 1990; 37(4):443-6. DOI: 10.1002/ajmg.1320370402. View

Jin N, Wu Y, Meng Q, Luo Q . Prenatal diagnosis of tuberous sclerosis complex: Echocardiography, cranial magnetic resonance, and genetic testing of 40 cases with fetal cardiac tumors. Heliyon. 2023; 9(6):e16980. PMC: 10361035. DOI: 10.1016/j.heliyon.2023.e16980. View

Qaderi S, Javinani A, Blumenfeld Y, Krispin E, Papanna R, Chervenak F . Mammalian target of rapamycin inhibitors: A new-possible approach for in-utero medication therapy. Prenat Diagn. 2024; 44(1):88-98. DOI: 10.1002/pd.6492. View

10.

Larson A, Hedgire S, Deshpande V, Stemmer-Rachamimov A, Harisinghani M, Ferrone C . Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex. Clin Genet. 2011; 82(6):558-63. DOI: 10.1111/j.1399-0004.2011.01805.x. View

11.

Mowrey K, Northrup H, Rougeau P, Hashmi S, Krueger D, Ebrahimi-Fakhari D . Frequency, Progression, and Current Management: Report of 16 New Cases of Nonfunctional Pancreatic Neuroendocrine Tumors in Tuberous Sclerosis Complex and Comparison With Previous Reports. Front Neurol. 2021; 12:627672. PMC: 8062856. DOI: 10.3389/fneur.2021.627672. View

12.

International Society of Ultrasound in Obstetrics and Gynecology , Carvalho J, Allan L, Chaoui R, Copel J, DeVore G . ISUOG Practice Guidelines (updated): sonographic screening examination of the fetal heart. Ultrasound Obstet Gynecol. 2013; 41(3):348-59. DOI: 10.1002/uog.12403. View

13.

Yinon Y, Chitayat D, Blaser S, Seed M, Amsalem H, Yoo S . Fetal cardiac tumors: a single-center experience of 40 cases. Prenat Diagn. 2010; 30(10):941-9. DOI: 10.1002/pd.2590. View

14.

Milon V, Malinge M, Blanluet M, Tessarech M, Battault C, Prestwich S . Diagnosis of tuberous sclerosis in the prenatal period: a retrospective study of 240 cases and review of the literature. Eur J Hum Genet. 2024; 32(12):1590-1598. PMC: 11606953. DOI: 10.1038/s41431-024-01631-w. View

15.

Tworetzky W, McElhinney D, Margossian R, Moon-Grady A, Sallee D, Goldmuntz E . Association between cardiac tumors and tuberous sclerosis in the fetus and neonate. Am J Cardiol. 2003; 92(4):487-9. DOI: 10.1016/s0002-9149(03)00677-5. View

16.

Franz D, Capal J . mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders. Orphanet J Rare Dis. 2017; 12(1):51. PMC: 5348752. DOI: 10.1186/s13023-017-0596-2. View

17.

Miwa K, Iwai S, Nagashima T . Management of neonatal cardiac rhabdomyoma obstructing the aortic valve. J Card Surg. 2022; 37(9):2839-2841. DOI: 10.1111/jocs.16702. View

18.

Mustafa H, Javinani A, Morning M, DAntonio F, Pagani G, Puranik P . Characteristics and Outcomes of Fetal Cardiac Rhabdomyoma With or Without mTOR Inhibitors, a Systematic Review and Meta-Analysis. Prenat Diagn. 2024; 44(10):1251-1267. DOI: 10.1002/pd.6640. View

19.

Goergen S, Fahey M . Prenatal MR Imaging Phenotype of Fetuses with Tuberous Sclerosis: An Institutional Case Series and Literature Review. AJNR Am J Neuroradiol. 2022; 43(4):633-638. PMC: 8993194. DOI: 10.3174/ajnr.A7455. View

20.

Hulshof H, Slot E, Lequin M, Breuillard D, Boddaert N, Jozwiak S . Fetal Brain Magnetic Resonance Imaging Findings Predict Neurodevelopment in Children with Tuberous Sclerosis Complex. J Pediatr. 2021; 233:156-162.e2. DOI: 10.1016/j.jpeds.2021.02.060. View